2012
Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target
Treger R, Cook A, Rai G, Maloney D, Simeonov A, Jadhav A, Thomas C, Williams D, Cappello M, Vermeire J. Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target. International Journal For Parasitology Drugs And Drug Resistance 2012, 2: 171-177. PMID: 22844653, PMCID: PMC3404738, DOI: 10.1016/j.ijpddr.2012.05.001.Peer-Reviewed Original ResearchAncylostoma ceylanicumVivo anthelminthic efficacyIntestinal worm burdenEffective drug therapyGlutathione reductasePrimary targetOral treatmentSevere anemiaDrug therapyHookworm infectionHookworm Ancylostoma ceylanicumAntischistosomal compoundsHamster modelNovel chemotherapyTrematode parasite Schistosoma mansoniWorm burdenGrowth delayHookworm diseaseParasite Schistosoma mansoniEx vivoParasitic diseasesParasite deathA. ceylanicumSchistosoma mansoniWeight gainA furoxan – amodiaquine hybrid as a potential therapeutic for three parasitic diseases
Mott BT, Cheng KC, Guha R, Kommer VP, Williams DL, Vermeire JJ, Cappello M, Maloney DJ, Rai G, Jadhav A, Simeonov A, Inglese J, Posner GH, Thomas CJ. A furoxan – amodiaquine hybrid as a potential therapeutic for three parasitic diseases. RSC Medicinal Chemistry 2012, 3: 1505-1511. PMID: 23205265, PMCID: PMC3509744, DOI: 10.1039/c2md20238g.Peer-Reviewed Original ResearchParasitic diseasesEx vivo assaysAntimalarial drug amodiaquineNovel therapiesEffective treatmentParasite Plasmodium falciparumSchistosoma mansoniAncylostoma ceylanicumParasitic targetsPotential therapeuticsMultiple mechanismsVivo assaysDiseaseFrequent emergenceAmodiaquineTherapyHuman populationMansoniFalciparum
1996
Molecular Approaches to Vaccinating against Hookworm Disease
Hotez P, Hawdon J, Cappello M, Jones B, Ghosh K, Volvovitz F, Shu-Hua X. Molecular Approaches to Vaccinating against Hookworm Disease. Pediatric Research 1996, 40: 515-521. PMID: 8888276, DOI: 10.1203/00006450-199610000-00001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLarval antigensVaccine antigensInfective hookworm larvaeProtective immunityHookworm infectionAdjuvant formulationsDrug chemotherapyAlternative vaccinesVaccine routeLive vaccineGenetic immunizationVaccine developmentHookworm larvaeHookworm diseaseParasitic diseasesAntigenPhase IVaccineAncylostoma caninumProtein 1ImmunizationTarget populationAcceptable approachDiseaseASP-2